Divi’s Laboratories has announced that its Unit-I manufacturing facility located in Lingojigudem Village, Telangana, underwent inspection by the US Food and Drug Administration (US-FDA) from November 10, 2025, to November 14, 2025. The company reported that the inspection, which was a general cGMP review, concluded with no 483 observations.
US-FDA Inspection Concludes
Divi’s Laboratories has completed an inspection by the US Food and Drug Administration (US-FDA) at its Unit-I manufacturing facility in Lingojigudem Village, Yadadri Bhuvanagiri district, Telangana. The inspection took place between November 10, 2025 and November 14, 2025.
Inspection Outcome
The US-FDA conducted a general current Good Manufacturing Practice (cGMP) inspection. Following the conclusion of the inspection, Divi’s Laboratories reported that there were no 483 observations made by the agency. This indicates a successful inspection outcome for the company.
Source: BSE
